Presenters: Nicholas J. Vogelzang, MD; Robert Kilbourn, MD, PhD; Robert C. Flanigan, MD; Gerald W. Chodak, MD, FACS; Howard A. Burris, III, MD
Discuss the role of single agent chemotherapy or second line hormonal therapy for managing hormone refractory prostate cancer; describe results of clinical trials using combinations chemotherapy for metastatic, hormone-refractory prostate cancer; review the role of taxanes in treating metastatic disease. Be familiar with the most recent data for treating prostate cancer.
|